Drugs / Sovaprevir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01180790 | Sep 2010 → Mar 2012 | chronic hepatitis C virus infection | Alexion Pharmaceuticals, Inc. | Completed | Mixed |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01849562 Comparator | Apr → Nov 2013 | chronic hepatitis C virus infection | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sovaprevir | “ACH-0141625 (Sovaprevir)” NCT01180790 ↗ |
| Known as | ACH-0141625 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01180790 ↗ |
| Action | Inhibit | “Nonstructural protein 3/4A protease inhibitor.” NCT01849562 ↗ |
| Modality | Small molecule | — CHEMBL2105750 ↗ |
| Route | Oral | “200 mg oral capsule once daily” NCT01180790 ↗ |